RxDoctor Payments Data

Assad Mukhtar, MD

Psychiatry · Saint Louis, MONPI 1609259001

Payments from drug & device makers

$1,063in general payments, 2019–2025

Across 54 payments — averaging $19.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$426
  • Neurocrine Biosciences, Inc.$181
  • Johnson & Johnson$98
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$76
  • Lundbeck LLC$75
  • Otsuka America Pharmaceutical, Inc.$44
  • plus $163 from 7 others

What the payments were for

  • Food & beverage$1,063100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,063 in reported general payments places this provider in the 70th percentile of 680 psychiatry providers in Missouri.

See all psychiatry providers in Missouri

Medicare billing

Part B allowed, 2024
$9,148
Medicare patients
40
Services billed
136

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate18$169,651
Aripiprazole26$2,225
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine26$967
Mirtazapine26$659
Bupropion XlBupropion Hcl26$651
Olanzapine27$608
Methylphenidate Hcl20$459
Trazodone Hcl29$441
Lamotrigine27$401
Quetiapine Fumarate ErQuetiapine Fumarate11$368
Clonazepam44$350
Quetiapine Fumarate26$349
Venlafaxine Hcl ErVenlafaxine Hcl31$342
Alprazolam46$293
Duloxetine Hcl20$287

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$181$169,65118 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 680 psychiatry providers in Missouri.

Other psychiatry in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →